Compass Therapeutics (CMPX) Other Gross PP&E Adjustments (2019 - 2026)
Compass Therapeutics recorded quarterly Other Gross PP&E Adjustments of -$1.9 million in Q1 2026, up 18.43% quarter-over-quarter from -$2.4 million in Q4 2025, and down 929.74% year-over-year from $232000.0 in Q1 2025.
Compass Therapeutics' Other Gross PP&E Adjustments history runs 8 years deep, the most recent figure standing at -$1.9 million for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments fell 929.74% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$1.9 million (down 929.74% YoY), while the FY2025 annual figure was -$2.4 million, down 13782.35% from the prior year.
- Other Gross PP&E Adjustments came in at -$1.9 million for Q1 2026 at Compass Therapeutics, up from -$2.4 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $6.0 million in Q2 2024 to a low of -$3.1 million in Q2 2025.
- A 5-year average of $2.2 million and a median of $3.5 million in 2022 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments jumped 365.91% in 2022 and sank 13782.35% in 2025, its largest moves.
- Compass Therapeutics' Other Gross PP&E Adjustments stood at $4.2 million in 2022, then advanced by 29.29% to $5.4 million in 2023, then tumbled by 100.32% to -$17000.0 in 2024, then tumbled by 13782.35% to -$2.4 million in 2025, then climbed by 18.43% to -$1.9 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$1.9 million, -$2.4 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.93 Mn |
| Mar 31, 2026 | -1.93 Mn |
| Dec 31, 2025 | -2.36 Mn |
| Dec 31, 2025 | -2.36 Mn |
| Sep 30, 2025 | -2.71 Mn |
| Sep 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Mar 31, 2025 | 232,000.00 |
| Mar 31, 2025 | 232,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Sep 30, 2024 | 259,000.00 |
| Sep 30, 2024 | 259,000.00 |
| Jun 30, 2024 | 6.01 Mn |
| Jun 30, 2024 | 6.01 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 5.39 Mn |
| Dec 31, 2023 | 5.39 Mn |
| Sep 30, 2023 | 5.07 Mn |
| Sep 30, 2023 | 5.07 Mn |
| Jun 30, 2023 | 4.76 Mn |
| Jun 30, 2023 | 4.76 Mn |
| Mar 31, 2023 | 4.46 Mn |
| Mar 31, 2023 | 4.46 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 3.82 Mn |
| Sep 30, 2022 | 3.82 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 3.50 Mn |
| Mar 31, 2022 | 3.50 Mn |
| Dec 31, 2021 | 2.47 Mn |
| Dec 31, 2021 | 2.47 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 751,000.00 |
| Mar 31, 2021 | 751,000.00 |
| Dec 31, 2020 | 6.45 Mn |
| Dec 31, 2020 | 6.45 Mn |
| Sep 30, 2020 | 8.97 Mn |
| Sep 30, 2020 | 8.97 Mn |
| Jun 30, 2020 | 8.51 Mn |
| Jun 30, 2020 | 8.51 Mn |
| Dec 31, 2019 | 9.24 Mn |
| Dec 31, 2019 | 9.24 Mn |